ArticleNeoplasia (New York, N.Y.)2012
Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus.
Article in Neoplasia (New York, N.Y.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Biomarker Use in Barrett's Esophagus Surveillance.The American journal of gastroenterology · 2026Review
- Value of circulating free DNA methylation in the diagnosis of esophageal cancer: A systematic review and meta-analysis.Oncology letters · 2025Article
- Therapy response monitoring in blood plasma from esophageal adenocarcinoma patients using cell-free DNA methylation profiling.Scientific reports · 2024Article
- Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?Cancer communications (London, England) · 2021Review
- Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors.Epigenetics insights · 2020Review
- Etiology, cancer stem cells and potential diagnostic biomarkers for esophageal cancer.Cancer letters · 2019Review
- Cell-free DNA testing: future applications in gastroenterology and hepatology.Therapeutic advances in gastroenterology · 2019Review
- Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer.Journal of biomedical research · 2018Article
- Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives.Seminars in cancer biology · 2018Review
- Liquid Biopsy in Thyroid Cancer: New Insight.International journal of hematology-oncology and stem cell research · 2018Review
- Liquid biopsy for pediatric central nervous system tumors.NPJ precision oncology · 2018Review
- Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.Cancer discovery · 2018Article
- A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.Clinical epigenetics · 2018Article
- The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies.Frontiers in oncology · 2018Review
- Fibroblasts derived from oesophageal adenocarcinoma differ in DNA methylation profile from normal oesophageal fibroblasts.Scientific reports · 2017Article
- Methylation analyses in liquid biopsy.Translational lung cancer research · 2016Review
- Cell-free circulating tumor DNA in cancer.Chinese journal of cancer · 2016Review
- Identification of tissue-specific cell death using methylation patterns of circulating DNA.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Epigenome-wide profiling of DNA methylation in paired samples of adipose tissue and blood.Epigenetics · 2016Article
- Risk factors affecting the Barrett's metaplasia-dysplasia-neoplasia sequence.World journal of gastrointestinal endoscopy · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Aberrant DNA methylation (DNAm) is a feature of most types of cancers. Genome-wide DNAm profiling has been performed successfully on tumor tissue DNA samples. However, the invasive procedure limits the utility of tumor tissue for epidemiological studies. While recent data indicate that cell-free circulating DNAm (cfDNAm) profiles reflect DNAm status in corresponding tumor tissues, no studies have examined the association of cfDNAm with cancer or precursors on a genome-wide scale. The objective of this pilot study was to evaluate the putative significance of genome-wide cfDNAm profiles in esophageal adenocarcinoma (EA) and Barrett esophagus (BE, EA precursor). We performed genome-wide DNAm profiling in EA tissue DNA (n = 8) and matched serum DNA (n = 8), in serum DNA of BE (n = 10), and in healthy controls (n = 10) using the Infinium HumanMethylation27 BeadChip that covers 27,578 CpG loci in 14,495 genes. We found that cfDNAm profiles were highly correlated to DNAm profiles in matched tumor tissue DNA (r = 0.92) in patients with EA. We selected the most differentially methylated loci to perform hierarchical clustering analysis. We found that 911 loci can discriminate perfectly between EA and control samples, 554 loci can separate EA from BE samples, and 46 loci can distinguish BE from control samples. These results suggest that genome-wide cfDNAm profiles are highly consistent with DNAm profiles detected in corresponding tumor tissues. Differential cfDNAm profiling may be a useful approach for the noninvasive screening of EA and EA premalignant lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.